HC Wainwright Issues Optimistic Forecast for INKT Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for MiNK Therapeutics in a research report issued to clients and investors on Friday, August 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.35) per share for the quarter, up from their prior forecast of ($0.63). HC Wainwright currently has a “Buy” rating and a $35.00 target price on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.93) EPS, FY2027 earnings at ($1.97) EPS, FY2028 earnings at ($2.39) EPS, FY2029 earnings at ($1.67) EPS and FY2030 earnings at $0.06 EPS.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.02).

Other research analysts have also issued research reports about the company. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research lowered shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Weiss Ratings upgraded shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, MiNK Therapeutics has a consensus rating of “Hold” and an average price target of $35.00.

MiNK Therapeutics Stock Performance

NASDAQ INKT opened at $11.22 on Tuesday. The stock’s fifty day moving average is $11.33 and its two-hundred day moving average is $11.21. The firm has a market capitalization of $55.88 million, a P/E ratio of -4.67 and a beta of 0.48. MiNK Therapeutics has a fifty-two week low of $8.48 and a fifty-two week high of $16.98.

Hedge Funds Weigh In On MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC purchased a new position in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned 0.55% of MiNK Therapeutics at the end of the most recent quarter. 2.87% of the stock is currently owned by institutional investors and hedge funds.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.